Publications by authors named "David Cirelli"

Claim this Profile
A
A novel in-vitro expression assay by LC/MS/MS enables multi-antigen mRNA vaccine characterization.
Hanliu Leah Wang, Kimia Kajbaf, Brian C Gau, Andrew W Dawdy, Rachel Edwards, David Cirelli

Sci Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2.
Brian C Gau, Andrew W Dawdy, Hanliu Leah Wang, Bradley Bare, Carlos H Castaneda, David J Cirelli

Sci Rep· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of BNT162b2 mRNA to Evaluate Risk of Off-Target Antigen Translation.
Himakshi K Patel, Kun Zhang, Rachael Utegg, Elaine Stephens, Shauna Salem, David J Cirelli

J Pharm Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists' Perspective.
Lavinia M Lewis, Advait V Badkar, David Cirelli, Rodney Combs, Thomas F Lerch

J Pharm Sci· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for Setting Patient-Centric Commercial Specifications for Biotherapeutic Products.
Margaret N Ruesch, Luca Benetti, Eileen Berkay, David J Cirelli, Neha Frantz

J Pharm Sci· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.
Lindsay B Avery, Jason Wade, Mengmeng Wang, Amy Tam, Amy King, David Cirelli

MAbs· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity.
Sandeep Kumar, Kirk Roffi, Dheeraj S Tomar, David Cirelli, Nicholas Luksha

Protein Eng Des Sel· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Yao-Te Hsieh, Poonam Aggarwal, David Cirelli, Ling Gu, Teresa Surowy

J Immunol Methods· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis